UBC-led study gives hope for COVID-19 treatment
Scientists around the world, including Canada, are working tirelessly on the development and testing of new treatments and vaccines to help contain the current outbreak of COVID-19. Among them is UBC’s Dr. Josef Penninger. He is the senior scientist leading an international research team that has found a trial drug which effectively blocks the cellular door that the novel coronavirus uses to infect its hosts. The team’s findings hold promise for a treatment capable of stopping early infection of COVID-19.
On April 8, 2020, Dr. Penninger participated in our second COVID-19 webinar and shared insights into this cutting-edge research and the hope it offers in the global fight against the virus. The conversation was moderated by Mary Lynn Young, Associate Professor, UBC School of Journalism; Co-Founder, The Conversation Canada.
UBC Expert
Dr. Josef Penninger – Director, Life Sciences Institute; Professor and Canada 150 Research Chair in Functional Genetics, UBC Faculty of Medicine
Recorded April 8, 2020.
Supported by:
Please support the UBC President’s Pandemic Recovery Initiative
The effects of the COVID-19 global pandemic have been immediate and far-reaching—but together we can support each other and quickly adapt to rapidly changing circumstances. As a world-leading research university with a deep commitment to our students, we find ourselves in a position of strength to meet the challenges brought on by the pandemic. UBC is responding to the situation by creating the UBC President’s Pandemic Recovery Initiative, which encompasses funds to provide emergency relief for students and accelerate advanced research. Please join others in the UBC community as we face this immense challenge head on by contributing to one of the two opportunities if you can. With your help, we can get through this—together.